TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30439945

Group type: EXPERIMENTAL
Intervention: WHO dose pole for praziquantel (PZQ) dosing
Number of subjects: 9827

Group type: EXPERIMENTAL
Intervention: Modified dose pole for praziquantel (PZQ) dosing
Number of subjects: 9827
Study: 27133379

Group type: EXPERIMENTAL
Intervention: SEPT9 gene methylation assay
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: SEPT9 gene methylation assay combined with carcinoembryonic antigen
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: SEPT9 gene methylation assay combined with fecal immunochemical test
Number of subjects: 1031

Group type: COMPARATOR
Intervention: Epi proColon 2.0
Number of subjects: 1031
Study: 25643511

Group type: EXPERIMENTAL
Intervention: 2-week anti-HP therapy plus 90-day oral iron
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2-week anti-HP therapy alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: 90-day oral iron alone
Number of subjects: 60
Study: 23515583

Group type: EXPERIMENTAL
Intervention: Tropisetron add-on to risperidone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo add-on to risperidone
Number of subjects: 40
Study: 19825906

Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 19006730

Group type: EXPERIMENTAL
Intervention: MF-IOL
Number of subjects: 495

Group type: COMPARATOR
Intervention: CM-IOL
Number of subjects: 495
Study: 15689407

Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 12182253

Group type: EXPERIMENTAL
Intervention: Ibuprofen arginate 200 mg
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Ibuprofen arginate 400 mg
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study: 10367716

Group type: COMPARATOR
Intervention: Heat-induced dehydration (D)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Exercise-induced dehydration (E)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glycerol hyperhydration (H)
Number of subjects: 8
Study: 8607674

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (Duraflo II)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Uncoated circuits
Number of subjects: 20
Study: 1833245

Group type: EXPERIMENTAL
Intervention: Nafarelin 800 micrograms/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nafarelin 400 micrograms/d
Number of subjects: 16

Group type: COMPARATOR
Intervention: Danazol 800 mg/d
Number of subjects: 16
Study: 7139067

Group type: EXPERIMENTAL
Intervention: S-carboxymethylcysteine in hard gelatin capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: S-carboxymethylcysteine syrup
Number of subjects: 0
Study: 30088162

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen plus thoracic epidural analgesia (TEA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA) alone
Number of subjects: 120
Study: 28946075

Group type: EXPERIMENTAL
Intervention: Perceived benefit from condom use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived cost of condom use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cusp model
Number of subjects: 0
Study: 25654431

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 77576
Study: 24306437

Group type: EXPERIMENTAL
Intervention: High-resolution (HR) practice when walking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-resolution (LR) practice when walking
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-resolution (HR) practice when using a wheelchair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-resolution (LR) practice when using a wheelchair
Number of subjects: 0
Study: 22553919

Group type: EXPERIMENTAL
Intervention: Capsicum plasters on bilateral HT 7 acupoints
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inactive plasters (sham)
Number of subjects: 50
Study: 19129989

Group type: EXPERIMENTAL
Intervention: Acetaminophen 15 mg/kg/dose (n=112)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.5 mg/kg/dose (n=105)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg/dose (n=84)
Number of subjects: 301
Study: 18028119

Group type: EXPERIMENTAL
Intervention: Pseudoexfoliation syndrome (PEX)
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Age group 50-59 years
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Age group > or = 80 years
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Eyes with PEX
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Central corneal thickness, anterior chamber depth, lens thickness, nuclear lens opacifications, optic disc morphology
Number of subjects: 1045
Study: 15385923

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) given as adjunct to chemotherapy (ATRA-arm, n=122)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Intensive consolidation therapy (n=31)
Number of subjects: 242

Group type: COMPARATOR
Intervention: No ATRA (standard-arm, n=120)
Number of subjects: 242
Study: 11125238

Group type: EXPERIMENTAL
Intervention: Tacrine 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11806464

Group type: EXPERIMENTAL
Intervention: Perindopril (4 or 8 mg once daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nitrendipine (20 or 40 mg once daily)
Number of subjects: 46
Study: 9060122

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 74) - clinicians were strongly requested not to hospitalize for suspected IUGR if the Doppler findings were normal
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (n = 76) - standard management for suspected IUGR without revealing Doppler results
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study: 7822984

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (200 mg of oral vitamin E for 4-8 weeks)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Thalassemic patients (compared to 16 normal controls)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Thalassemic patients (Hb H disease)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Thalassemic patients (Hb H disease and beta‐thal/Hb E)
Number of subjects: 65
Study: 2869648

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 200 mg labetalol
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 53
Study: 31672420

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 20
Study: 29248384

Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine + Hydrochlorothiazide (TAH) 40/5 mg + 12.5 mg
Number of subjects: 310

Group type: COMPARATOR
Intervention: Telmisartan/Amlodipine (TA) 40/5 mg
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine + Hydrochlorothiazide (TAH)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Telmisartan/Amlodipine (TA)
Number of subjects: 310
Study: 27640138

Group type: EXPERIMENTAL
Intervention: High neutrophil-to-lymphocyte ratio (NLR) ≥3.0
Number of subjects: 393
Study: 24670273

Group type: EXPERIMENTAL
Intervention: Monocanalicular silicone intubation (MCI)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bicanalicular silicone intubation (BCI)
Number of subjects: 38
Study: 22907229

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 14
Study: 20135214

Group type: EXPERIMENTAL
Intervention: Healthy Love Workshop (HLW)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Comparison workshop
Number of subjects: 313
Study: 18769354

Group type: COMPARATOR
Intervention: EVG/r alone (200/100 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVG added to TPV/r (500/200 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVG added to DRV/r (600/100 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVG/r (200/100 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EVG/r (125/100 mg once daily)
Number of subjects: 0
Study: 16145283

Group type: EXPERIMENTAL
Intervention: Vitamin E emulsion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 10
Study: 12020337

Group type: EXPERIMENTAL
Intervention: 30 g/d of alcohol for 8 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 15 g/d of alcohol for 8 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: 0 g/d of alcohol for 8 weeks
Number of subjects: 63
Study: 10519499

Group type: EXPERIMENTAL
Intervention: One-sided informed consent
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Prerandomized consent to experimental treatment
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Prerandomized consent to standard treatment
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: One-sided physician-modified informed consent
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: One-sided patient-modified informed consent
Number of subjects: 770

Group type: COMPARATOR
Intervention: Control group (one-sided informed consent)
Number of subjects: 770
Study: 8537265

Group type: EXPERIMENTAL
Intervention: Meropenem 1 g tds iv
Number of subjects: 221

Group type: COMPARATOR
Intervention: Ceftazidime 2 g tds iv
Number of subjects: 221
Study: 1958005

Group type: EXPERIMENTAL
Intervention: Phadebas radioallergosorbent test (PhRAST)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Pharmacia CAP System (CAP)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: modified RAST (mRAST)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: modified RAST (mRAST) with threshold raised to class 2
Number of subjects: 128
Study: 29610221

Group type: EXPERIMENTAL
Intervention: ILM insertion technique
Number of subjects: 41

Group type: COMPARATOR
Intervention: Inverted ILM flap technique
Number of subjects: 41
Study: 27916242

Group type: EXPERIMENTAL
Intervention: Pregabalin and methylcobalamin combination (PG‐B12)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diclofenac potassium (DP)
Number of subjects: 100
Study: 25416241

Group type: EXPERIMENTAL
Intervention: 5 days' voice rest
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 10 days' voice rest
Number of subjects: 31
Study: 23890528

Group type: EXPERIMENTAL
Intervention: Type I trimming technique (1-cm incision, glandular and subcutaneous tissue removal using scissors)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Type II trimming technique (4-5-cm incision, trimming under direct vision)
Number of subjects: 150
Study: 23013746

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with 20 mg/kg alglucosidase alfa biweekly
Number of subjects: 69
Study: 20128370

Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Drug Eluting Stent (DES)
Number of subjects: 295
Study: 17541390

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg (dose titrated to 300 mg if needed)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Lisinopril 20 mg (dose titrated to 40 mg if needed)
Number of subjects: 183
Study: 15361558

Group type: EXPERIMENTAL
Intervention: SMART stent
Number of subjects: 203

Group type: COMPARATOR
Intervention: Wallstent
Number of subjects: 203
Study: 11302613

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control site (no fibrin sealant)
Number of subjects: 0
Study: 9724486

Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy aimed at near normoglycemia
Number of subjects: 0
Study: 7979840

Group type: EXPERIMENTAL
Intervention: Acarbose (50 to 300 mg three times per day)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 2692090

Group type: EXPERIMENTAL
Intervention: cyclosporin A
Number of subjects: 7
Study: 825076

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three intravenous doses of 600 mug of TRH over 15 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated challenges with TRH
Number of subjects: 0
Study: 30517975

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Number of subjects: 36

Group type: COMPARATOR
Intervention: PTFE sutures
Number of subjects: 36
Study: 27791532

Group type: EXPERIMENTAL
Intervention: Rational emotive behaviour therapy (REBT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Attentional placebo (ATP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no sessions)
Number of subjects: 62
Study: 25726502

Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.25 mg/kg (maximum 25 mg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Alteplase 0.9 mg/kg (maximum 90 mg)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 104

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 104
Study: 23904396

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 109

Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: EAT volume increase
Number of subjects: 109
Study: 21481381

Group type: EXPERIMENTAL
Intervention: Cystectomy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Coagulation
Number of subjects: 48
Study: 19807152

Group type: EXPERIMENTAL
Intervention: Xanthone-rich mangosteen liquid (59 mL)
Number of subjects: 0
Study: 16731547

Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate and testosterone undecanoate injections
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 90
Study: 15301643

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 90
Study: 10910852

Group type: EXPERIMENTAL
Intervention: IV verapamil 2.5 mg and morphine 5 mg added to lidocaine solution (Group 3)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: IV morphine 5 mg and verapamil 2.5 mg added to lidocaine solution (Group 4)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: verapamil 2.5 mg and morphine 5 mg added to lidocaine solution (Group 5)
Number of subjects: 75

Group type: COMPARATOR
Intervention: IV saline (Group 1)
Number of subjects: 75
Study: 9071903

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (160 mg daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 8418770

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy
Number of subjects: 0
Study: 3738977

Group type: EXPERIMENTAL
Intervention: Reinforcement of the doctor's advice by a nurse
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Written instructions to the patients
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 150
Study: 30509862

Group type: EXPERIMENTAL
Intervention: Uni HIIT program (n=26)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Wait-list control (n=27)
Number of subjects: 53
Study: 29330977

Group type: EXPERIMENTAL
Intervention: Peer-Assisted Learning (PAL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Expert-Assisted Learning (EAL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pre-test
Number of subjects: 120
Study: 25882376

Group type: EXPERIMENTAL
Intervention: Thrombectomy with stent retriever plus intravenous t-PA
Number of subjects: 196

Group type: COMPARATOR
Intervention: Intravenous t-PA alone (control group)
Number of subjects: 196
Study: 24195220

Group type: EXPERIMENTAL
Intervention: Acupressure at Jiaji points
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication group (pinaverium bromide tablet)
Number of subjects: 60
Study: 21509914

Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive-Compulsive Scale Symptom Checklist (YBOCS-SC)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Factor analysis including mental compulsions and reassurance-seeking
Number of subjects: 201
Study: 17940545

Group type: EXPERIMENTAL
Intervention: Soy + probiotic (yoghurt)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Soy + prebiotic (resistant starch)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control soy diet
Number of subjects: 36
Study: 16322964

Group type: EXPERIMENTAL
Intervention: Wide excision plus asymmetric modified Limberg flap (Group 2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Wide excision plus classic Limberg flap (Group 1)
Number of subjects: 68
Study: 15526809

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LPS inhalation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline inhalation
Number of subjects: 15
Study: 11295905

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 46
Study: 9203722

Group type: EXPERIMENTAL
Intervention: Monovalent type 1 oral poliovirus vaccine (OPV) at 6 months and trivalent OPV at 7 and 9 months (Group 1)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: OPV at birth and 3 doses of OPV and inactivated poliovirus vaccine (IPV) (Group 2)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo at birth and 3 doses of IPV (Group 3)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Monovalent type 1 OPV following 3 IPV doses (Group 2)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Trivalent OPV (Group 1)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 547
Study: 7703709

Group type: EXPERIMENTAL
Intervention: Orientation Group intervention to reduce waiting time for treatment
Number of subjects: 0
Study: 3237852

Group type: EXPERIMENTAL
Intervention: Balloon inflated with 400 ml or more of water
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Balloon capacity measurement
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Correlation of stomach capacity to spontaneous food intake
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Correlation of stomach capacity to balloon volume needed to suppress 50% of spontaneous intake
Number of subjects: 8
Study: 31206595

Group type: EXPERIMENTAL
Intervention: Repeated open application test (ROAT) with fragrance mix I
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Algorithm indicating positive contact allergy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Patch test reactivity to fragrance mix I
Number of subjects: 109
Study: 30014535

Group type: EXPERIMENTAL
Intervention: Empowerment-oriented social group work intervention (9 group sessions focusing on capacity building and increasing individual competences, environmental resources and opportunities)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 27052688

Group type: EXPERIMENTAL
Intervention: IV metoprolol (15 mg bolus)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: IV metoprolol (25 min before reperfusion)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control (IV vehicle)
Number of subjects: 218
Study: 24997587

Group type: EXPERIMENTAL
Intervention: MRI assessment every 6 months
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: X-ray assessment every 6 months
Number of subjects: 186

Group type: COMPARATOR
Intervention: Sham-intervention
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 186
Study: 22120766

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 20100808

Group type: EXPERIMENTAL
Intervention: EQ-assisted pharmacist counseling
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: EQ plus 8 weeks of nicotine transdermal patch (EQ+)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Observation-only group (OBS)
Number of subjects: 300
Study: 18448221

Group type: EXPERIMENTAL
Intervention: Appearance-based sun protection intervention with UV photo and photoaging information
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Appearance-based sun protection intervention with both injunctive and descriptive norms information
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 125
Study: 15741547

Group type: EXPERIMENTAL
Intervention: Glucantime (20 mg of antimony [Sb]/kg/day intravenously for 20 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pentamidine (2 mg/kg every other day for seven injections)
Number of subjects: 80
Study: 11838918

Group type: EXPERIMENTAL
Intervention: Brief Intervention plus Booster session (BIB)
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 539
Study: 9990361

Group type: EXPERIMENTAL
Intervention: SDZ ASM 981 (1.0%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SDZ ASM 981 (0.3%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clobetasol-17-propionate (0.05%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ointment base (placebo)
Number of subjects: 10
Study: 7996960

Group type: EXPERIMENTAL
Intervention: 200 ppb sulphur dioxide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 400 ppb nitrogen dioxide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of 200 ppb sulphur dioxide and 400 ppb nitrogen dioxide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 10
Study: 3414518

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 57

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 57
Study: 29859917

Group type: EXPERIMENTAL
Intervention: Low dose lithium (150-600 mg) targeting a blood level of 0.2-0.6 mmol/L
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0